Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms

作     者：Iñaki Etxeberria Irene Olivera Elixabet Bolaños Asunta Cirella Álvaro Teijeira Pedro Berraondo Ignacio Melero Inaki Etxeberria;Irene Olivera;Elixabet Bolaños;Asunta Cirella;Álvaro Teijeira;Pedro Berraondo;Ignacio Melero

作者机构：Program of Immunology and ImmunotherapyCenter for Applied Medical Research(CIMA)PamplonaSpain Navarra Institute for Health Research(IDISNA)PamplonaSpain Centro de Investigación Biomédica en Red de Cáncer(CIBERONC)MadridSpain Department of Immunology and ImmunotherapyClínica Universidad de NavarraPamplonaSpain 

基　　金：Fundación Científica Asociación Española Contra el Cáncer, AECC Ministerio de Economía y Competitividad, MINECO, (SAF 2017-83267-C2-1R) Ministerio de Economía y Competitividad, MINECO 

出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)

年 卷 期：2020年第17卷第6期

页      码：576-586页

摘      要：Gene engineering and combinatorial approaches with other cancer immunotherapy agents may confer capabilities enabling full tumor rejection by adoptive T cell therapy(ACT).The provision of proper costimulatory receptor activity and cytokine stimuli,along with the repression of inhibitory mechanisms,will conceivably make the most of these treatment *** this sense,T cells can be genetically manipulated to become refractory to suppressive mechanisms and exhaustion,last longer and differentiate into memory T cells while endowed with the ability to traffic to malignant *** antitumor effects can be dramatically augmented with permanent or transient gene transfer maneuvers to express or delete/repress genes.A combination of such interventions seeks the creation of the ultimate bionic T cell,perfected to seek and destroy cancer cells upon systemic or local intratumor delivery.

主 题 词：Adoptive cell therapy T cell engineering Cancer immunotherapy 

学科分类：1001[医学-基础医学] 100102[100102] 10[医学] 

核心收录：

D　O　I：10.1038/s41423-020-0464-1

馆 藏 号：203919690...